Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Moderate Buy” by Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.80.

Several analysts have issued reports on XERS shares. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Barclays began coverage on Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective for the company. Finally, Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th.

Insiders Place Their Bets

In other news, Director John Johnson sold 135,400 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the transaction, the director directly owned 698,083 shares of the company’s stock, valued at approximately $5,040,159.26. This represents a 16.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $6.25, for a total value of $104,168.75. Following the sale, the insider owned 1,226,507 shares of the company’s stock, valued at approximately $7,665,668.75. This represents a 1.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 240,308 shares of company stock worth $1,732,453. Insiders own 4.56% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers boosted its stake in Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after purchasing an additional 1,735 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Xeris Biopharma by 7.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock worth $150,000 after acquiring an additional 2,264 shares during the period. Royal Bank of Canada grew its stake in Xeris Biopharma by 6.5% during the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after purchasing an additional 2,351 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of Xeris Biopharma by 17.7% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after purchasing an additional 2,420 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Trading Down 3.6%

NASDAQ XERS opened at $5.60 on Thursday. Xeris Biopharma has a one year low of $3.81 and a one year high of $10.08. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The company has a market capitalization of $965.61 million, a price-to-earnings ratio of -559.44 and a beta of 0.61. The company’s 50-day simple moving average is $7.06 and its two-hundred day simple moving average is $7.57.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $85.81 million during the quarter, compared to analysts’ expectations of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. Equities analysts forecast that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.